TT - Theatre

The session aims to provide a practical understanding of how to recognise, assess, and manage patients with MASLD, particularly those at risk of progressive liver disease.

This promotional session is organised and funded by Recordati Pharmaceuticals Limited. Professor Derek Connolly has received a speaker honorarium from Recordati for this presentation.

Using recognisable patient scenarios, this session asks a practical question: can a patient appear well controlled based on today’s measurements while carrying a higher long-term metabolic burden? We will follow this question from the consulting room to the evidence, examining discordance between conventional risk assessment and Skin Autofluorescence (SAF). The session then turns to practice: which patients might benefit from AGE measurement, what could an unexpectedly high result trigger, and what is needed to integrate this information into existing CVRM and perioperative pathways?

.